CoChat

Microglial activation in Parkinson’s disease using [18F]-FEPPA

Open access

The DOI matches its Crossref record; 45 of the 47 references it cites were found in a registry or an index.

Abstract

Neuroinflammatory processes including activated microglia have been reported to play an important role in Parkinson’s disease (PD). Increased expression of translocator protein (TSPO) has been observed after brain injury and inflammation in neurodegenerative diseases. Positron emission tomography (PET) radioligand targeting TSPO allows for the quantification of neuroinflammation in vivo. Based on the genotype of the rs6791 polymorphism in the TSPO gene, we included 25 mixed-affinity binders (MABs) (14 PD patients and 11 age-matched healthy controls (HC)) and 27 high-affinity binders (HABs) (16 PD patients and 11 age-matched HC) to assess regional differences in the second-generation radioligand [18F]-FEPPA between PD patients and HC. FEPPA total distribution volume (V T) values in cortical as well as subcortical brain regions were derived from a two-tissue compartment model with arterial plasma as an input function. Our results revealed a significant main effect of genotype on [18F]-FEPPA V T in every brain region, but no main effect of disease or disease × genotype interaction in any brain region. The overall percentage difference of the mean FEPPA V T between HC-MABs and HC-HABs was 32.6% (SD = 2.09) and for PD-MABs and PD-HABs was 43.1% (SD = 1.21). Future investigations are needed to determine the significance of [18F]-FEPPA as a biomarker of neuroinflammation as well as the importance of the rs6971 polymorphism and its clinical consequence in PD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12974-016-0778-1

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Graphs of partial volume effect corrected (PVEC) total distribution volume (V T) in different brain regions. Healthy control with mixed affinity binder (HC-MAB) and healthy control with high affinity binder (HC-HAB) groups as well as Parkinson’s disease with mixed affinity binder (PD-MAB) and Parkinson’s disease with high affinity binder (PD-HAB) groups. Asterisks indicate that the HAB groups show significantly higher V T mean values compared with the MAB groups
Fig. 1 Graphs of partial volume effect corrected (PVEC) total distribution volume (V T) in different brain regions. Healthy control with mixed affinity binder (HC-MAB) and healthy control with high affinity binder (HC-HAB) groups as well as Parkinson’s disease with mixed affinity binder (PD-MAB) and Parkinson’s disease with high affinity binder (PD-HAB) groups. Asterisks indicate that the HAB groups show significantly higher V T mean values compared with the MAB groupsCC BY · PubMed Central
Fig. 2 Graphs of partial volume effect corrected (PVEC) total distribution volume (V T) in different brain regions. Healthy control with mixed affinity binder (HC-MAB) and healthy control with high affinity binder (HC-HAB) groups as well as Parkinson’s disease with mixed affinity binder (PD-MAB) and Parkinson’s disease with high affinity binder (PD-HAB) groups. Asterisks indicate that the HAB groups show significantly higher V T mean values compared with the MAB groups
Fig. 2 Graphs of partial volume effect corrected (PVEC) total distribution volume (V T) in different brain regions. Healthy control with mixed affinity binder (HC-MAB) and healthy control with high affinity binder (HC-HAB) groups as well as Parkinson’s disease with mixed affinity binder (PD-MAB) and Parkinson’s disease with high affinity binder (PD-HAB) groups. Asterisks indicate that the HAB groups show significantly higher V T mean values compared with the MAB groupsCC BY · PubMed Central
Fig. 3 Graphs of partial volume effect corrected (PVEC) total distribution volume (V T) in different brain regions. Healthy control with mixed affinity binder (HC-MAB) and healthy control with high affinity binder (HC-HAB) groups as well as Parkinson’s disease with mixed affinity binder (PD-MAB) and Parkinson’s disease with high affinity binder (PD-HAB) groups. Asterisks indicate that the HAB groups show significantly higher V T mean values compared with the MAB groups
Fig. 3 Graphs of partial volume effect corrected (PVEC) total distribution volume (V T) in different brain regions. Healthy control with mixed affinity binder (HC-MAB) and healthy control with high affinity binder (HC-HAB) groups as well as Parkinson’s disease with mixed affinity binder (PD-MAB) and Parkinson’s disease with high affinity binder (PD-HAB) groups. Asterisks indicate that the HAB groups show significantly higher V T mean values compared with the MAB groupsCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 45 references

Cited by

See all 113

Metadata

Authors
Ghadery, C., Koshimori, Y., Coakeley, S., Harris, M., Rusjan, P., Kim, J., Houle, S., & Strafella, A. P.
Affiliations
  • Centre for Addiction and Mental Health (CA)
  • University Health Network (CA)
Corresponding author
Strafella, Antonio P.
Venue
Journal of Neuroinflammation
Published
2017-01-11
Volume
14
Issue
1
Pages
8-8
ISSN
1742-2094 (ISSN-L)
OpenAlex
W2577460502
Cited by
113
References
47
Citations by year
2026: 4 · 2025: 10 · 2024: 3 · 2023: 11 · 2022: 16 · 2021: 13 · 2020: 19 · 2019: 17 · 2018: 12 · 2017: 8
FWCI
7.63
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Journal of Neuroinflammation (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • TSpace (University of Toronto) (submittedVersion, cc-by)
Funders
Canadian Institutes of Health Research (INE 117891)
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords
Parkinson's disease, microglial activation, neuroinflammation, [18F]FEPPA, translocator protein (TSPO), PET radiotracer, volume of distribution, high-affinity binders, two-tissue compartment model, biomarkers
MeSH terms
Aged, Anilides, Brain, Female, Fluorine Radioisotopes, Humans, Male, Middle Aged, Parkinson Disease, Pyridines, Severity of Illness Index, Case-Control Studies, Microglia, Receptors, GABA, Polymorphism, Single Nucleotide, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Microglial activation in Parkinson’s disease using [18F]-FEPPA. https://app.cochat.ai/papers/10.1186/s12974-016-0778-1
The paper
Ghadery, C., Koshimori, Y., Coakeley, S., Harris, M., Rusjan, P., Kim, J., Houle, S., & Strafella, A. P. (2017). Microglial activation in Parkinson’s disease using [18F]-FEPPA. Journal of Neuroinflammation. https://doi.org/10.1186/s12974-016-0778-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.